Coinbase
COIN
MicroStrategy
MSTR
Meta Platforms
META
Apple
AAPL
Amazon
AMZN
US Stock MarketDetailed Quotes
VTYX Ventyx Biosciences
- 2.440
- -0.080-3.17%
Trading Dec 3 10:11 ET
172.53MMarket Cap-1038P/E (TTM)
2.530High2.370Low289.93KVolume2.500Open2.520Pre Close701.62KTurnover0.58%Turnover RatioLossP/E (Static)70.71MShares11.48052wk High0.62P/B121.12MFloat Cap1.67052wk Low--Dividend TTM49.64MShs Float47.251Historical High--Div YieldTTM6.35%Amplitude1.670Historical Low2.419Avg Price1Lot Size
About Ventyx Biosciences Company
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded on November 21, 2018 and is headquartered in San Diego, CA.
Company Profile
SymbolVTYX
Company NameVentyx Biosciences
Listing DateOct 21, 2021
Issue Price16.00
Founded2018
CEODr. Raju S. Mohan, PhD
MarketNASDAQ
Employees80
Fiscal Year Ends12-31
Address12790 El Camino Real,Suite 200
CitySan Diego
ProvinceCalifornia
CountryUnited States of America
Zip Code92130
Phone1-760-593-4832
Websitehttp://www.ventyxbio.com
Company Executives
- Name
- Position
- Salary
- Dr. Raju S. Mohan, PhD
- Director, Chief Executive Officer and President
- 9.41M
- Matthew Richard Moore
- Chief Operating Officer
- --
- Dr. John M. Nuss, PhD
- Chief Scientific Officer
- 3.89M
- Dr. Sheila Gujrathi, M.D.
- Executive Chairman of the Board
- 486.29K
- Dr. Allison J. Hulme, PhD
- Director
- 834.42K
- Onaiza Cadoret-Manier
- Independent Director
- 837.34K
- Somasundaram Subramaniam, M.B.A.
- Independent Director
- 417.35K
- William R. White, J.D.
- Independent Director
- 416.29K
- Roy M. Gonzales
- Interim Principal Financial Officer and Interim Principal Accounting Officer
- --
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.